Most foreign specialty pharma companies still file in each Gulf market separately, sequencing national registrations one after another as if the centralized route doesn't exist. It does exist. It has existed since 1999. And it deserves a place in every Gulf entry plan — even the plans that ultimately, and correctly, decide not to use it.

The mechanism

The Gulf Central Committee for Drug Registration (GCC-DR), part of the Gulf Health Council, runs a centralized procedure that produces one joint assessment opinion recognized across all six member states: Saudi Arabia, the UAE, Kuwait, Oman, Qatar, and Bahrain. And since a 2020 circular, a reliance model applies to products already approved in at least two GCC countries — compressing the regional assessment to a target of around sixty days.

Sixty days for a regional approval. That number alone should change how a BD team sequences a Gulf entry.

6 4 2 0 Month 0 Month 6 Month 12 Month 18 Month 24 Country by country Anchor then reliance
Gulf markets unlocked over 24 months — sequential national filings vs. two anchor approvals followed by the reliance pathway.

There is a second piece most people miss. Centrally approved products and GCC-DR–accredited manufacturing sites become eligible to participate in the Gulf Group Purchasing tender — the centralized procurement channel run through the Gulf Health Council. So the registration pathway and the regional procurement pathway connect. One opens the door to the other.

The contrarian part

Now the part that matters, because most promotional content skips it: the centralized route is not always the fastest way in. National registration in Saudi Arabia and the UAE is often quicker and, for some companies, strategically preferred over the GCC-DR route. If your commercial priority is a single large market — Saudi Arabia first — going national there can beat the centralized file.

The centralized procedure earns its value when you want breadth: when six-market access and Gulf Group Purchasing eligibility are worth more to you than speed in one country.

That is the real decision. Not "centralized versus national" as an ideology — a sequencing question tied to where your volume actually sits.

What it costs to not map this

Here is what we have watched happen. A specialty company picks Saudi Arabia, registers nationally, builds a commercial presence — and only then discovers that a centralized file built on that Saudi approval plus one more GCC approval could have unlocked the other four markets in roughly sixty days. They left Kuwait, Oman, Qatar, and Bahrain on the table for two years, because nobody mapped the reliance pathway at the start.

For an orphan or specialty product with a small but real patient population in each Gulf state, those four markets are not rounding errors. Aggregate them, and the regional volume can change the entire business case for entry.

The companies that win the Gulf treat it as one regulatory and procurement system with national finishing steps — not six separate countries. Reliance pathways and harmonized submissions are a defining trend of the current GCC regulatory environment, and the direction of travel is clear.

The short version
  • The GCC-DR centralized procedure produces one joint approval recognized in all six Gulf states; a reliance model compresses it to around sixty days for products with two GCC approvals.
  • Central approval also opens the Gulf Group Purchasing tender — registration and regional procurement connect.
  • Centralized is not automatically fastest: national filing in Saudi Arabia or the UAE can beat it when one market dominates your case.
  • Map the reliance pathway before you commit a sequence — the cost of not mapping it is measured in markets and years.

The infrastructure to enter six markets at once is built. The question is whether your strategy is built to use it.

← All briefings